主页 > 医药生命 >
【drug-news】辉瑞资助上海生命科学研究院
Pfizer (NYSE: PFE) has teamed up with the Shanghai Institutes for Biological Sciences (SIBS) to do basic research. The biggest of pharmas will underwrite $500,000 of health-related basic research projects at SIBS for each of the next three years. Pfizer and SIBS will select the research projects jointly. According to a press release, that initiative is only part of the overall agreement, although no other collaborative activities were disclosed.
Pfizer took pains to point out that the financial commitment supported innovation in basic research and not in just “the last mile of drug development,” as Jeff Kindler, Pfizer’s CEO, put it. He was praising the commitment of his own company, but the partnership is an implicit validation of China’s innovation in basic science as well.
Pfizer said basic research remains a very valuable task for drug companies, even though the investigations do not always lead to marketable drugs. “Innovation in these areas has the potential to truly alter the way we look at healthcare over the next 20 years,” Kindler said in a statement, putting a more positive spin on the project.
The agreement with SIBS shows that Pfizer remains involved with indigenous scientific research entities, even though its Shanghai R&D facility, a center with over 330 staff members, is now operating. Pfizer’s China Research and Development Center is the largest China research facility operated by a multinational pharma.
“Strategic alliances such as this one are needed to increase the opportunities to produce the science, technology and product candidates that lead to new medicines,” said Al Gabor, regional president for Pfizer’s North Asia, India, Pakistan, and Thailand region.
Pfizer’s Shanghai center also collaborates with Peking University, Tsinghua University, Shanghai Jiaotong University, and multiple institutes of Chinese Academy of Sciences.
The Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences (CAS) was established in 1999, combining eight former CAS institutes of biological sciences in Shanghai. It comprises eight research institutes and three supporting units on six campuses, with a total staff over 2000, including 26 academicians of the Chinese Academy of Sciences and 4 academicians of the Chinese Academy of Engineering. It has more than 1800 graduate students and approximately 150 postdoctoral fellows. Research at SIBS is in three major fields: life science basic research, translational research on human health and major diseases, and research into sustainable development of agriculture and the environment. 本人认领此文. 如在48小时内未能提交译文, 其他战友自由认领. 如有疑问，请指正。谢谢
Pfizer Underwrites Basic Research at Shanghai Institutes
辉瑞同意资助上海生命科学研究院
Pfizer (NYSE: PFE) has teamed up with the Shanghai Institutes for Biological Sciences (SIBS) to do basic research. The biggest of pharmas will underwrite $500,000 of health-related basic research projects at SIBS for each of the next three years. Pfizer and SIBS will select the research projects jointly. According to a press release, that initiative is only part of the overall agreement, although no other collaborative activities were disclosed.
辉瑞已经同上海生命科学研究院（SIBS）联手进行基础科学研究，这个世界上最大的制药企业会在未来的三年中每年为SIBS提供50万美元来进行与健康相关的基础研究。辉瑞将和SIBS一同进行选题。据报道，这项协议只是总协议的一部分，虽然其他合作项目并没有透漏。
Pfizer took pains to point out that the financial commitment supported innovation in basic research and not in just “the last mile of drug development,” as Jeff Kindler, Pfizer’s CEO, put it. He was praising the commitment of his own company, but the partnership is an implicit validation of China’s innovation in basic science as well.
辉瑞CEO Jeff Kindler 说：辉瑞的投资并不局限于新药研发的最终阶段,还包括在早期对基本健康原理的创新探究。他高度赞扬了这次的合作，这次合作代表了辉瑞支持中国基础研发这一重大承诺。
Pfizer said basic research remains a very valuable task for drug companies, even though the investigations do not always lead to marketable drugs. “Innovation in these areas has the potential to truly alter the way we look at healthcare over the next 20 years,” Kindler said in a statement, putting a more positive spin on the project.
辉瑞说对于制药公司而言，基础研究时一项非常重要的任务，虽然这种类型的研究不一定能立即产生可观的商业收益，这些领域的创新有可能在未来的20年内改变我们看待健康的方式。这些合作项目具有非常积极的意义。
The agreement with SIBS shows that Pfizer remains involved with indigenous scientific research entities, even though its Shanghai R&D facility, a center with over 330 staff members, is now operating. Pfizer’s China Research and Development Center is the largest China research facility operated by a multinational pharma.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-25 05:11
医学,生命科学网